Pfizer
NEWS
Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.
Overall, Pfizer posted a good first quarter, with sales slightly higher and a 14 percent increase in profits due to lower restructuring costs and a significantly lower tax rate. However, revenue was below Wall Street expectations.
Pfizer launched a new ad that celebrates diversity in its employment.
Is it possible for the pharma industry to invest too much money into research and development projects for one disease area? In an online essay Jay Bradner, president of Novartis’ Institutes for BioMedical Research, expressed some concern, particularly in areas like cancer research.
The biopharma industry is starting to leverage mobile apps and other digital technologies to improve access to clinical trials. Novartis launched FocalView, an app for ophthalmic patients involved in eye-related clinical trials.
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies. Last week BioSpace reported that China expects to see exponential industry growth by 2022 and today Eli Lilly and Company added to that growth through a partnership with China’s National Center for Cardiovascular Diseases.
Last week, the FDA’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns. Not surprisingly, the Arthritis Advisory Committee’s recommendation yesterday was mixed, split right along safety concerns.
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
JOBS
IN THE PRESS